Mutant MYC Fusion Polypeptides for Cancer Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting MYC genes lack selectivity and efficacy, with existing inhibitors failing to effectively modulate MYC expression in cancer cells.
Innovation Solution
Development of fusion polypeptides combining mutant MYC polypeptides with regulatory domains, such as repressor domains, to enhance the inhibitory effect on MYC expression by fusing them to modulate MYC activity and induce apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitor treatments are used to target MYC genes, then treatment is provided, but the treatments lack selectivity and efficacy in modulating MYC expression
Solution Approach 1:
The patent combines a mutant MYC polypeptide (which competitively blocks MYC:MAX binding to E boxes) with a repressor domain to create a fusion polypeptide. This merging of two functional elements - the MYC-binding capability and the transcriptional repression capability - results in a compound molecule that both targets MYC specifically and potently represses its activity, thereby resolving the contradiction between efficacy and selectivity
Solution Approach 2:
The fusion polypeptide represents a composite molecular structure combining two distinct functional domains: the mutant MYC portion that provides target recognition and binding specificity, and the repressor domain that provides potent transcriptional inhibition. This composite structure achieves both high selectivity (through the MYC-specific binding) and high efficacy (through the strong repression mechanism) simultaneously
2Reliability
If a mutant MYC polypeptide is used to block MYC:MAX binding, then MYC activity is inhibited, but the inhibitory effect is insufficient without additional regulatory domains
Solution Approach 1:
The patent merges the mutant MYC polypeptide with a repressor domain into a single fusion polypeptide molecule. This combination allows the polypeptide to perform multiple functions - binding to MYC:MAX complexes and actively repressing transcription - thereby enhancing the inhibitory effect while maintaining a manageable structural complexity through covalent linkage
3Reliability
If fusion polypeptides with repressor domains are developed, then effectiveness in reducing MYC expression is increased, but the manufacturing and characterization complexity increases
Solution Approach 1:
The fusion polypeptide design uses universal, well-characterized repressor domains (such as KRAB domains) that can be systematically applied to different mutant MYC variants. This modular approach allows for relatively straightforward manufacturing and characterization, as the repressor domain components are standardized and their functions are well-understood, thereby mitigating the complexity issue while maintaining high effectiveness
Data Source
AI summary
The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.